Cargando…

Correction: Successful rituximab treatment for severe rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive juvenile dermatomyositis: a case report and literature review

Detalles Bibliográficos
Autores principales:	Nishi, Kentaro, Ogura, Masao, Tamai, Naotaka, Gima, Masafumi, Ide, Kentaro, Koinuma, Goro, Kamei, Koichi, Ito, Shuichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9446570/ https://www.ncbi.nlm.nih.gov/pubmed/36064710 http://dx.doi.org/10.1186/s12969-022-00736-0

Ejemplares similares

Successful rituximab treatment for severe rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive juvenile dermatomyositis: a case report and literature review
por: Nishi, Kentaro, et al.
Publicado: (2022)

Immunogenicity and safety of SARS-CoV-2 mRNA vaccine in patients with nephrotic syndrome receiving immunosuppressive agents
por: Kamei, Koichi, et al.
Publicado: (2022)

Central venous catheter infection-related glomerulonephritis under long-term parenteral nutrition: a report of two cases
por: Okada, Mari, et al.
Publicado: (2016)

Effective Administration of Rituximab in Anti-MDA5 Antibody–Positive Dermatomyositis with Rapidly Progressive Interstitial Lung Disease and Refractory Cutaneous Involvement: A Case Report and Literature Review
por: Ogawa, Yuka, et al.
Publicado: (2017)

Interstitial lung disease in clinically amyopathic dermatomyositis with and without anti-MDA-5 antibody: to lump or split?
por: Ikeda, Satoshi, et al.
Publicado: (2015)

Two cases of idiopathic steroid-resistant nephrotic syndrome complicated with thrombotic microangiopathy
por: Nishi, Kentaro, et al.
Publicado: (2020)

Rituximab in Antimelanoma Differentiation-Associated Protein-5 Dermatomyositis with Interstitial Lung Disease
por: Scirocco, Chiara, et al.
Publicado: (2020)

Management of MDA-5 antibody-positive dermatomyositis with interstitial lung disease—an Auckland case series
por: Dick, Michael, et al.
Publicado: (2021)

Anti-MDA5 Associated Clinically Amyopathic Dermatomyositis With Rapidly Progressive Interstitial Lung Disease
por: Tavakolian, Kameron, et al.
Publicado: (2022)

82 Juvenile dermatomyositis with early-onset anti-MDA 5 antibodies: a case report
por: Ayad, N, et al.
Publicado: (2022)

Mechanic’s Hand Heralding Relapse in an Indian Adolescent with Anti-MDA5 Positive Juvenile Dermatomyositis
por: Ganatra, Keya, et al.
Publicado: (2022)

Rapid and sustained response to JAK inhibition in a child with severe MDA5 + juvenile dermatomyositis
por: Strauss, Timmy, et al.
Publicado: (2023)

Machine learning for screening and predicting the risk of anti-MDA5 antibody in juvenile dermatomyositis children
por: Xue, Yuan, et al.
Publicado: (2023)

Intramuscular lesions in musculoskeletal MRI as a favourable prognostic sign in patients with anti-MDA5 antibody-positive dermatomyositis
por: Oto, Yohsuke, et al.
Publicado: (2023)

Roles of biomarkers in anti‐MDA5‐positive dermatomyositis, associated interstitial lung disease, and rapidly progressive interstitial lung disease
por: Li, Xiaomeng, et al.
Publicado: (2022)

Juvenile Dermatomyositis
por: Rhim, Jung Woo
Publicado: (2022)

2. Two cases of anti-MDA5 positive dermatomyositis with rapidly progressive interstitial lung disease
por: Levasseur, Kirsty, et al.
Publicado: (2019)

Fast-Onset Diffuse Interstitial Lung Disease in Anti-MDA5 Antibodies-Associated Amyopathic Dermatomyositis
por: Aissaoui, Houari, et al.
Publicado: (2021)

P12 A case of MDA5-positive Juvenile Dermatomyositis complicated by Macrophage Activation Syndrome
por: Twynam-Perkins, Elizabeth, et al.
Publicado: (2022)

Clinical nomogram assisting in discrimination of juvenile dermatomyositis-associated interstitial lung disease
por: Hu, Minfei, et al.
Publicado: (2023)

Combination Therapy with Rituximab, Tofacitinib and Pirfenidone in a Patient with Rapid Progressive Interstitial Lung Disease (RP-ILD) Due to MDA5 Antibody-Associated Dermatomyositis: A Case Report
por: Yen, Tsai-Hung, et al.
Publicado: (2021)

Adolescent-onset anti-MDA5 antibody-positive juvenile dermatomyositis with rapidly progressive interstitial lung disease and spontaneous pneumomediastinum: a case report and literature review
por: Yeung, Tsz-Wing, et al.
Publicado: (2021)

7. Anti-MDA5 associated dermatomyositis
por: Laverty, Ursula, et al.
Publicado: (2019)

Editorial: Anti-MDA5-Positive Dermatomyositis
por: Gono, Takahisa, et al.
Publicado: (2022)

Case of lipoatrophic diabetes induced by juvenile dermatomyositis
por: Baba, Yusuke, et al.
Publicado: (2017)

Successful treatment of plasma exchange for rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis: A case report
por: Endo, Yushiro, et al.
Publicado: (2018)

Anti-MDA5 antibody-positive dermatomyositis with rapidly progressive interstitial lung disease: report of two cases
por: Mehta, Asmita A, et al.
Publicado: (2021)

Risk Prediction for Rapidly Progressive Interstitial Lung Disease in Anti-MDA5-Positive Dermatomyositis: The CRAFT Model
por: Guo, Jinqiang, et al.
Publicado: (2023)

The Serum Ferritin Level Is Associated with the Treatment Responsivity for Rapidly Progressive Interstitial Lung Disease with Amyopathic Dermatomyositis, Irrespective of the Anti-MDA5 Antibody Level
por: Osawa, Takeshi, et al.
Publicado: (2017)

Dermatomyositis with Rapidly Progressive Interstitial Lung Disease Treated with Rituximab: A Report of 3 Cases in Japan
por: Tokunaga, Kenichiro, et al.
Publicado: (2017)

Juvenile Dermatomyositis in Pregnancy
por: Madu, Anthony Emeka, et al.
Publicado: (2013)

The Vasculopathy of Juvenile Dermatomyositis
por: Papadopoulou, Charalampia, et al.
Publicado: (2018)

Pneumomediastinum in MDA5-associated clinically amyopathic dermatomyositis
por: Kotsiou, Ourania S., et al.
Publicado: (2017)

Therapiealternativen bei amyopathischer MDA5-positiver Dermatomyositis
por: Schumacher, Falk, et al.
Publicado: (2023)

Clinical Features of Anti-MDA5 Antibody-positive Rapidly Progressive Interstitial Lung Disease without Signs of Dermatomyositis
por: Sakamoto, Noriho, et al.
Publicado: (2018)

Anti-MDA5 Antibody-positive Clinically Amyopathic Dermatomyositis Complicated by Unilateral Right-sided Interstitial Lung Disease
por: Kori, Mayuko, et al.
Publicado: (2020)

Aberrantly Expressed Galectin-9 Is Involved in the Immunopathogenesis of Anti-MDA5-Positive Dermatomyositis-Associated Interstitial Lung Disease
por: Liang, Lin, et al.
Publicado: (2021)

A Computed Tomography Radiomics-Based Prediction Model on Interstitial Lung Disease in Anti-MDA5-Positive Dermatomyositis
por: Xu, Wenwen, et al.
Publicado: (2021)

Clinically amyopathic dermatomyositis with interstitial lung disease double-positive for anti-MDA5 and anti-PL12 antibodies
por: Hiramatsu, Toshiya, et al.
Publicado: (2022)

Assessment of anti-MDA5 antibody as a diagnostic biomarker in patients with dermatomyositis-associated interstitial lung disease or rapidly progressive interstitial lung disease
por: Li, Liubing, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_hb1prasleb72qs9ts6005g3684